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Critical respiratory eventsAbstract The current prospective comparative study aimed at the clinical outcome of sugammadex
reversal of neuromuscular blockade (NMB) and the evaluation of its impact on the frequency of
critical respiratory events during sevoﬂurane anesthesia.
Patients and methods: The study included 100 male patients with mean age of 33.1 ± 7.5 years; 67
patients of ASA grade I, 27 patients of ASA grade II and 6 patients of ASA grade III. Patients were
randomly allocated to two equal groups: Group N received reversal of NMB using intravenous (IV)
neostigmine (6 lg/kg) and Group S received IV sugammadex (2 mg/kg). After induction of anesthe-
sia, NM function was monitored, at the wrist; using the TOF-Watch-SX. At the end of the surgery,
the reversal of NMB assigned for each group was administered at least after 15 min after the last
dose of atracurium and NM monitoring was continued until recovery of the TOF T4/T1 ratio to
0.9. Time since injection of the reversal drug till recovery to TOF ratio of 0.9 was recorded and
critical respiratory events (CRE) were monitored.
Results: Both groups showed non-signiﬁcant difference as regards the frequency of patients
required top doses of NMBD or the mean number of top doses of NMBD. Time till achievement
of TOF ratio of 0.9 was signiﬁcantly shorter with sugammadex compared to neostigmine.
Moreover, mean time to achieve TOF ratio of 0.9 was 2.76 ± 1.5 min with sugammadex, but
was 9.78 ± 2 min with neostigmine with signiﬁcant difference in favor of sugammadex. CRE were
recorded in 5 patients (5%); 3 patients with neostigmine (6%) and 2 patients (4%) with sugamma-
dex.
Conclusion: NMB reversal using sugammadex allowed signiﬁcantly earlier achievement of TOF
ratio of 0.9 in signiﬁcantly higher number of patients with minimally and acceptable respiratory
events at PACU in comparison with neostigmine.
ª 2013 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists.
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C1. Introduction
The problem of residual neuromuscular blockade dates since
the introduction of general anesthesia and the use of neuro-
muscular blockers; earlier studies reported a 6-fold increased
risk of death in the perioperative period in association with
96 H.I.A. Nagy, H.W. Elkadithe use of neuromuscular blocking drugs (NMBD) [1]. There-
after, the advances in manufacturing of NMBD in parallel
with development of new inhalational anesthetics promoted
the use of general anesthesia and lessened its risks [2,3].
Despite the application of techniques proven to limit the de-
gree of residual paralysis as the use of intermediate-acting
NMBD and pharmacological reversal, up to 33–64% of pa-
tients have evidence of inadequate neuromuscular recovery
on arrival to the post-anesthetic care unit (PACU) [4–6]. Ace-
tylcholinesterase inhibitors, such as neostigmine and edropho-
nium carry a risk of unwanted effects, such as bradycardia,
hypotension, broncho-constriction and hyper-salivation. These
side effects were opposed by the concomitant use of anticholin-
ergic drugs, such as atropine or glycopyrrolate, but anticholin-
ergic drugs have their inherent side effects as tachycardia,
blurred vision and sedation, and so should be administered
cautiously especially in high risk and elderly patients [7–9].
Studies in volunteers have demonstrated that train-of-four
(TOF) fade ratios <0.7–0.9 are associated with upper airway
obstruction, inadequate recovery of pulmonary function, re-
duced pharyngeal muscle coordination, an increased risk for
aspiration and an impaired hypoxic ventilatory response
[10,11].
Sugammadex, a water-soluble, modiﬁed speciﬁcally de-
signed c-cyclodextrin, the ﬁrst of a new class of selective relax-
ant binding drugs developed for the rapid and complete
reversal of neuromuscular blockade induced by aminosteroid
NMBD. Sugammadex acts by encapsulating unbound mole-
cules of NMBD, thus reducing its free fraction and preventing
them from binding to nicotinic receptors in the neuromuscular
junction thus inducing rapid reversal of their effect [12–14].
Clinical studies of sugammadex in surgical patients have
shown that sugammadex provides effective, dose-dependent
reversal of both moderate and deep/intense rocuronium-in-
duced neuromuscular blockade during propofol maintenance
anesthesia. Sevoﬂurane is widely used in clinical practice and
enhances neuromuscular blockade, the safety and efﬁcacy of
various doses of sugammadex under maintenance anesthesia
with volatile drugs remain largely unknown especially after
administration at deep neuromuscular blockade [15–17].
The current prospective comparative study aimed at the
clinical outcome of sugammadex reversal of neuromuscular
blockade and the evaluation of its impact on the frequency
of critical respiratory events during sevoﬂurane anesthesia.TR
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2. Patients and methods
The current study was conducted at Anesthesia department,
Kasr Al-Aini University Hospital since January 2011 till Octo-
ber 2011. After approval of the study protocol by the local
Ethical Committee and obtaining written fully informed pa-
tients’ consent, 100 adult male patients assigned to undergo
open abdominal surgical procedures were enrolled in the
study. Patients with cardiac, renal or hepatic diseases or sensi-
tivity to used drugs were not enrolled in the study.
Patients were assigned using sealed envelopes, allocated to
two equal groups (n= 50): Group N included patients who re-
ceived reversal of NMB in the form of intravenous (IV) neo-
stigmine in dose of 6 lg/kg and 10 lg/kg of atropine while
Group S included patients who received reversal of NMB
using IV sugammadex in dose of 2 mg/kg.
REAll patients were premedicated with IV atropine 0.6 mg and
midazolam 1–2 mg 5 min before induction of anesthesia. Before
induction, patients were preoxygenated and base line mean
arterial blood pressure (MAP), heart rate (HR), respiratory rate
(RR) and peripheral arterial O2 saturation (SaO2) were re-
corded. Anesthesia was induced with propofol
1.5–2.5 mg/kg and fentanyl 0.5–1 lg/kg. Then, neuromuscular
function was monitored, at the wrist; using the TOF-Watch-
SX (Schering-Plough Corporation, Swords-Dublin, Ireland).
Brieﬂy, according to good clinical research practice in pharma-
codynamic studies of NMBD [18], the device was stabilized by
using repetitive TOF stimulation for 1 min followed by 50 Hz
titanic stimulation given for 5 s, and repetitive TOF stimulation
for 3–4 min. After calibration of the device atracurium
0.5 mg/kg was given and the trachea was intubated when the re-
sponse to TOF stimulation ceased. Top up doses of atracurium
of 0.1 mg/kg were used as required upon reappearance of the
second twitch (T2) in a TOF to maintain neuromuscular block-
ade during the operation. Ventilation was controlled and min-
ute ventilation was adjusted to maintain end tidal CO2 at
35 ± 5 mmHg. Anesthesia was maintained with sevoﬂurane
2–4%. Lactated Ringer’s solution at a rate of 10 ml/kg/hr was
given during anesthesia and 2 ml/kg/hr after anesthesia until
patients tolerated oral ﬂuids. At the end of the surgery, the
reversal of NMB assigned for each group was administered at
least 15 min after the last dose of atracurium (with the appear-
ance of the fourth contraction of the TOF) and neuromuscular
monitoring was continued until recovery of the TOF T4/T1
ratio to 0.9. Following extubation patients were maintained
on supplemental O2 until awake in the recovery room.
Time since injection of the reversal drug till recovery to
TOF ratio of 0.9 was recorded. Critical respiratory events were
monitored and included the following items: requirement for
intervention for upper airway obstruction, occurrence of
hypoxemia categorized according to SaO2, the presence of
manifestations of respiratory distress, need for re-intubation
in the recovery room and/or the presence of manifestations
of pulmonary aspiration.
2.1. Statistical analysis
Obtained data were presented as mean ± SD, ranges, numbers
and ratios and median values. Results were analyzed using
Wilcoxon’s ranked test for unrelated data (Z test) and Chi-
square test. Statistical analysis was conducted using the SPSS
(Version 15, 2006) for Windows statistical package. P value
<0.05 was considered statistically signiﬁcant.
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The study included 100 male patients with mean age
of 33.1 ± 7.5; range: 28–52 years. There were 67 patients of
ASA grade I, 27 patients of ASA grade II and 6 patients
of ASA grade III. Details of patients’ enrollment data are
presented in Table 1 showing a non-signiﬁcant (p> 0.05)
difference between both study groups.
There was non-signiﬁcant (p> 0.05) difference between
both study groups as regards mean operative time and total
dose consumed of NMBD (Table 2). Fifty-six patients (56%)
required top doses of NMBD; 24 patients (48%) in group N
and 32 patients (64%) in group S with non-signiﬁcant
Table 1 Patients’ enrollment data.
Data Group N Group S Total
Age (years) 32 ± 6.7 (29–52) 34.1 ± 8.1 (28–49) 33.1 ± 7.5 (28–52)
Weight (kg) 84.5 ± 5.9 (69–92) 83.2 ± 7.7 (66–93) 83.8 ± 6.8 (66–93)
Height (cm) 167.5 ± 2.5 (165–181) 165.7 ± 3.2 (162–179) 166.6 ± 3 (162–181)
BMI (kg/m2) 30.1 ± 2.1 (25–33.8) 30.3 ± 2.9 (23.7–35.4) 30.2 ± 2.5 (23.7–35.4)
ASA grade Grade I 35 (70%) 32 (64%) 67 (67%)
Grade II 13 (26%) 14 (28%) 27 (27%)
Grade III 2 (4%) 4 (8%) 6 (6%)
Data are presented as mean ± SD and number; ranges and percentages are in parenthesis.
A non-signiﬁcant (p> 0.05) difference between both study groups.
Table 2 Operative data.
Data Group N Group S
Operative time (min) 95.5 ± 22.4 (60–130) 91.2 ± 20.1 (65–150)
Total dose of NMBD 42.2 ± 2.9 (34.5–46) 41.6 ± 3.9 (33–47)
Number of patients required top doses of NMBD 29 (58%) 31 (62%)
Number of top doses 2.5 ± 1.8 (1–6) 2.7 ± 1.5 (1–5)
Data are presented as mean ± SD and number; ranges and percentages are in parenthesis.
A non-signiﬁcant (p> 0.05) difference between both study groups.
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Figure 1 Mean (+SD) time till reaching TOF ratio of 0.9.
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D(p> 0.05) difference between both groups. Mean number of
top doses of NMBD, also, showed non-signiﬁcant (p> 0.05)
difference between both groups, (Table 2).E
Table 3 Neuromuscular recovery data.
Data
Time to reach TOF ratio of 0.9 <3 min
3– < 5
5–7
8–9
10–12
13–14
Mean
Data are presented as mean ± SD and number; ranges and percentages
RTime till achievement of TOF ratio of 0.9 was signiﬁcantly
shorter (Z= 6.159, p< 0.001) with sugammadex compared
to neostigmine (Fig. 1). Moreover, only 5 patients (10%) in sug-
ammadex group reached TOF ratio of 0.9 within
5–7.5 min, 21 patients (42%) reached TOF ratio of 0.9 in range
of 3–5 min and24patients (52%) reachedTOFratio of 0.9 in less
than 3 min with a mean time for patients received sugammadex
to achieve TOF ratio of 0.9 of 2.76 ± 1.5 min. On the contrary,
only 4 patients (8%) reachedTOF ratio of 0.9within 5–7 min, 23
patients (46%) within 8–9 min, 18 patients (36%) within 10–
12 min and 5 patients (10%) achieved TOF ratio of 0.9 within
13–14 min with a mean time for patients received neostigmine
to achieve TOF ratio of 0.9 of 9.78 ± 2 min, (Table 3).
All enrolled patients completed the study; CRE were re-
corded in 5 patients (5%); 3 patients with neostigmine (6%)
and 2 patients (4%) with sugammadex. One patient in neostig-
mine group developed severe hypoxemia with SaO2 85% de-
spite the oxygenation in line with signs of aspiration and was
recovered on application of oral airway, repeated suction,
more atropinization and increasing O2 ﬂow. This patient re-
quired additional dose of neostigmine till achieved TOF of
>0.9 and was capable of breathing spontaneously. The other
CGroup N Group S
0 24 (48%)
0 21 (42%)
4 (8%) 4 (8%)
23 (46%) 1 (2%)
18 (36%) 0
5 (10%) 0
9.78 ± 2 (5–14) 2.76 ± 1.5 (1.5–7.5)
are in parenthesis.
98 H.I.A. Nagy, H.W. Elkaditwo patients in neostigmine group and one patient in sug-
ammadex group developed moderate hypoxemia with SaO2
of 92%, 93% and 92%, respectively and responded to the
application of oral airway and increasing rate of O2 ﬂow.
The 2nd patient in sugammadex group required only jaw
thrust with maintenance on O2 mask till full recovery.4. Discussion
The problem concerning residual neuromuscular blockade is
mostly the development of critical respiratory events (CRE)
which usually occur in the post-anesthesia care unit (PACU).
The current study showed that the reversal of atracurium using
Sugammadex to achieve a TOF ratio of 0.9 took statistically
signiﬁcant less time than with neostigmine in a signiﬁcantly
higher number of patients with an overall lower rate of CRE
events. In fact, in the neostigmine group one patient experi-
enced severe hypoxemia.
In hand with the aim of the study and the reported out-
come, Murphy et al. [19,20] reported a frequency of residual
neuromuscular blockade of 4.5% in the PACU at TOF ratio
60.9 and concluded that incomplete neuromuscular recovery
is an important contributing factor in the development of ad-
verse respiratory events in the PACU. Thereafter, Murphy and
Brull [21] documented that clinical trials have demonstrated
that incomplete neuromuscular recovery during the early
postoperative period may result in acute respiratory events
(hypoxemia and airway obstruction), delays in tracheal extu-
bation, and an increased risk of postoperative pulmonary com-
plications. Also, Sauer et al. [22] out of their randomized,
prospective, placebo-controlled trial concluded that minimal
residual block was associated with hypoxemia in PACU.
Through the present study to exclude the impact of gender
on neuromuscular recovery, all enrolled patients were males
so that the difference in the outcome data could be attributed
to the type of reversal used. In support of this opinion, Heier
et al. [23] reported sex-related differences in the relationship be-
tween abductor pollicis TOF ratio and clinical measures ofmus-
cle function used to assess recovery from neuromuscular block.
Also, there was non-signiﬁcant difference between enrolled pa-
tients as regards constitutional, anesthetic and operative data.
Sugammadex was administered in a dose of 2 mg/kg; in line
with such dose Makri et al. [24] reviewed clinical trials concern-
ing dose-dependent effect of sugammadex and reported that the
suggested dose of sugammadex for reversal of shallow block
comes up to 2 mg/kg and 4 mg/kg for profound level of block.
The used dose of sugammadex allowed signiﬁcant shorter
neuromuscular recovery time compared to neostigmine with
a mean time till achievement of TOF ratio of 0.9 of 2.76 min
(166 s.). Such duration till recovery coincided with that re-
ported by Duvaldestin et al. [25] who reported a mean recovery
time of 3.2 and 2.8 min with sugammadex 2 mg/kg after rocu-
ronium and vecuronium NMB, respectively. Schaller et al. [26]
found sugammadex, 0.22 mg/kg, is able to reverse a TOF ratio
of 0.5–0.9 or higher in an average time of 2 min and within
5 min, 95% of patients reach this TOF ratio, while neostig-
mine, 34 lg/kg, is able to reverse a TOF ratio of 0.5–0.9 or
higher within 5 min. Lemmens et al. [27] detected that the
mean time to recovery of TOF ratio to 0.9 was 15-fold faster
with sugammadex (4.5 min) compared with neostigmine
(66.2 min) after profound vecuronium-induced block.
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tween visual loss of fade and return of TOF ratio >0.9 after
reversal of rocuronium block by neostigmine compared to sug-
ammadex which allowed a safer reversal of a moderate NMB
with signiﬁcantly shorter times of recovery. Also, Adamus et
al. [29] reported that after sugammadex and neostigmine, the
respective intervals until TOF ratioP0.90 were 2 and 15.9 min.
In hand with the obtained data, Gaszynski et al. [30] re-
ported a mean time to 90% of TOF for morbid obese patients
received rocuronium was 2.7 min with sugammadex and
9.6 min for neostigmine with signiﬁcant difference in favor of
sugammadex and concluded that administration of sugamma-
dex provides fast recovery of neuromuscular function in the
morbidly obese, however neostigmine does not. Sørensen et
al. [31] during rapid sequence induction and intubation, re-
ported that the median time from tracheal intubation to spon-
taneous ventilation and to 90% recovery of the ﬁrst twitch in
TOF were 406 s and 518 s with succinylcholine and 216 s and
168 s with rocuronium–sugammadex, respectively and con-
cluded that rapid sequence induction and intubation with
rocuronium followed by reversal with sugammadex allowed
earlier re-establishment of spontaneous ventilation than with
succinylcholine.
In support of the efﬁcacy and safety of NMB reversal using
sugammadex, its applicability in critical situation. Curtis et al.
[32] and Barbosa and da Cunha [33] presented case reported of
patient deteriorated from a ‘can’t intubate, can ventilate’ situ-
ation to a ‘can’t intubate, can’t ventilate’ situation and rocuro-
nium-induced neuromuscular block was successfully reversed
with sugammadex, as evidenced by the restoration of dia-
phragmatic movement, the ability of the patient to move her
limbs, and the presence of a train-of-four nerve stimulation
with no fade.
The obtained results concluded that neuromuscular block-
ade reversal of Atracurium under sevoﬂurane anesthesia using
sugammadex allowed signiﬁcantly earlier achievement of TOF
ratio of 0.9 in a signiﬁcantly higher number of patients with
minimal and acceptable respiratory events at PACU in com-
parison to neostigmine. Hence, Sugammadex improves the
reversal proﬁle of Atracurium under Sevoﬂurane anesthesia.
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